Which longevity startups have raised the most money?

Top startups in the longevity market ranked by total funding raised

Here is an updated table that ranks the top startups in the longevity market based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you need to dig deeper and get more detailed data, please check our report covering the longevity market.

1. Capital committed by investors at launch (January 2022), not necessarily all paid in; later rounds reported only by databases may be drawdowns of it and are not added.
2. Includes the primary proceeds of its IPO.
3. The company reported total funding at $150M (May 2023); our total sums disclosed equity rounds only (no debt, grants or unpaid commitments).
4. Press reports put total funding at $233M (Mar 2026), below the equity rounds we could source up to that date.
5. Press reports put total funding at $310M (Mar 2026); our total sums disclosed equity rounds only (no debt, grants or unpaid commitments).

Which longevity startups have raised the most money?

Altos Labs has raised the most money among longevity startups, with $3.0B committed at launch, followed by Oura with at least $1.5B and Neko Health with $1.0B.

The next group mixes consumer health and drug development. WHOOP, Insilico Medicine with $874M, NewLimit, and BioAge Labs with at least $522M have also raised substantial equity. Altos Labs is trying to rejuvenate cells; Oura and WHOOP sell connected health devices; Neko Health sells in-person preventive assessments; and Insilico Medicine develops drugs with AI. The names near the top are not all competing for the same customers.

Look at how they got there. Altos Labs announced its entire launch commitment in January 2022. Oura has accumulated funding through repeated rounds while selling smart rings and memberships. Neko Health has expanded through clinics and medical assessments, with its latest major financing linked to a US launch. NewLimit is putting new capital into medicines that still need human trials.

Manufacturing a wearable, staffing a clinic, and getting a medicine through trials all cost money in different ways. Our ranking puts those businesses side by side, even though their customers and timelines barely overlap.

Did Altos Labs raise all its longevity funding at launch?

Altos Labs lined up all of its longevity funding at launch in January 2022, as a single $3.0B commitment, while Oura has raised money across 10 rounds.

The word "committed" matters. Altos Labs announced that investors had fully committed the capital, not that the whole amount had already arrived in its bank accounts. Its launch statement described a research organization built around cellular rejuvenation, with scientists working across the San Francisco Bay Area, San Diego, Cambridge in the United Kingdom, and collaborators in Japan. Altos Labs described a long-term scientific program, without a near-term consumer product.

Oura has financed repeated expansions, while NewLimit is raising money for drug research. Altos Labs started with unusually deep support to assemble laboratories, recruit scientists, and investigate how cells might regain healthier function. Its early backing allowed Altos Labs to begin with an international research operation before selling any approved medicine.

The investors pledged the money for research that will take longer to judge than sales of smart rings or clinic appointments. The size of a launch commitment also tells us nothing about how much of it has already been paid out or spent.

Are most longevity startups raising far less than the biggest names?

Yes, 126 longevity startups have raised less than $100M, while just 3 have reached at least $1B.

Our ranking has 7 companies above $500M and 29 above $100M. The 126 companies below $100M account for 81% of the startups, and the median lifetime total is at least $13M. Most are operating with far less money than Altos Labs or Oura. We are comparing total equity raised across each company's history, not the size of one recent round or the market value of the business.

The gap partly reflects what companies are building. Altos Labs assembled a large basic-science effort from the start. NewLimit is developing a drug program that requires discovery work, manufacturing, and clinical studies. Meanwhile, biological-age testing ventures and specialist clinics can launch services with smaller initial financing, even if expanding them still costs money.

Oura's October 2025 financing followed strong ring sales and growing memberships, according to its announcement. Altos Labs attracted its launch commitment before developing a medicine it could sell. Altos Labs and Oura sit at the top of our ranking, but the businesses are at very different stages of earning revenue.

Are longevity wearables raising more than aging-drug startups?

Not across the board: WHOOP has raised $978M for a longevity wearable, but aging-drug developers Insilico Medicine ($874M) and NewLimit ($650M) are right there with it, and Altos Labs, which works on cellular rejuvenation, secured the largest commitment overall.

Look beyond Altos Labs and the contrast changes. NewLimit and Cambrian Biopharma are using substantial investor backing to pursue medicines tied to aging. On the consumer side, Oura, WHOOP, and Eight Sleep fund hardware, software, data collection, and subscriptions. These businesses can reach paying customers while pharmaceutical programs still face years of clinical work.

Oura has also moved beyond ring measurements. Dexcom announced a partnership in November 2024 to connect glucose-sensor data with Oura's sleep, activity, and health metrics. WHOOP's March 2026 funding announcement included healthcare organizations such as Abbott and Mayo Clinic among its investors. The companies are trying to turn daily measurements into a broader relationship with the user.

Wearables bring in sales earlier, but manufacturing and marketing also keep costs high.

The table below compares selected longevity business models by cumulative funding.

Startup	Raised	Rounds	Focus
Oura	$1.5B+	10	Smart ring
Neko Health	$1.0B	3	Health scans
WHOOP	$978M	8	Wearable
NewLimit	$650M	4	Reprogramming drugs
Human Longevity	$370M	4	Precision testing
Function Health	$343M+	2	Lab testing
Cambrian Biopharma	$284M+	4	Aging drugs
Eight Sleep	$250M	4	Smart sleep

A plus sign means that the recorded total is a minimum.

Why has Neko Health raised so much for longevity scans?

Neko Health has raised $1.0B for its longevity scanning business, including a $700M Series C in July 2026 to expand preventive clinics.

Neko Health combines body scanning, blood tests, its own equipment, and an appointment with clinical staff. In July 2026, the company said more than 100,000 people in Sweden and the United Kingdom had undergone a scan, while a much larger group had registered or joined a waitlist. The financing was intended to help open US locations and expand the service beyond its original markets.

This is a different bet from selling a health app alone. Neko Health must develop and maintain scanning equipment, recruit clinicians, and bring customers into physical sites. Its September 2026 announcement of a New York opening, with more US clinics planned, shows the kind of expansion the funding is supporting. The waitlist gives Neko Health potential customers as new clinics open.

The contrast with Prenuvo is instructive. Prenuvo uses whole-body MRI, whereas Neko Health focuses on its own noninvasive scanning system and clinical assessment. The American College of Radiology says the evidence does not yet justify routine total-body MRI screening for people without symptoms or known risk factors.

Has Oura raised more than WHOOP for longevity wearables?

Yes, Oura has raised at least $1.5B for its longevity wearable business, compared with WHOOP's $978M.

Oura's biggest financing announcement came in October 2025, when it reported at least $900M raised with Fidelity Management & Research Company leading the round. WHOOP then announced a $575M Series D+ in March 2026, led by Collaborative Fund, to expand its global personalized-health offering. Our ranking records Oura with 10 equity rounds and WHOOP with 8, so both have returned to investors over many years, unlike Altos Labs at launch.

The products also take different routes into healthcare. Oura emphasizes a ring, sleep and recovery insights, women's health, and integrations such as Dexcom's glucose data. WHOOP centers on a screenless wearable, training and recovery information, and a membership-based health platform. WHOOP's investor list includes healthcare institutions alongside financial investors and well-known athletes.

Oura postponed its planned IPO in September 2026 amid uncertain market conditions, according to the Associated Press. The proposed offering therefore adds nothing to its funding total.

Why do longevity reprogramming startups need so much money?

Longevity reprogramming research needs substantial funding before a drug can sell: NewLimit has raised $650M, and Life Biosciences at least $212M.

Reprogramming aims to change how aging cells behave at a biological level. NewLimit said its $435M Series C in June 2026, led by Founders Fund, would help bring its first medicine into human trials. The company has focused on older liver cells and has described progress on manufacturing and cellular experiments. The real test comes when researchers give a reprogramming medicine to people.

Life Biosciences offers a more advanced example. Life Biosciences raised an $80M Series D+ in April 2026 while moving ER-100 into a Phase 1 trial for optic neuropathies. In October 2026, Life Biosciences reported early tolerability observations from a small group of treated participants. The early results concern safety in glaucoma patients, not lifespan extension.

Other startups are pursuing autophagy, mitochondria, and the removal of senescent cells, so reprogramming is only part of the aging-drug business.

The table below shows selected longevity therapeutic developers, ordered by their cumulative equity funding.

Startup	Raised	Rounds	Focus
NewLimit	$650M	4	Reprogramming
Cambrian Biopharma	$284M+	4	Healthspan drugs
Life Biosciences	$212M+	5	Cell rejuvenation
Retro Biosciences	$180M+	2	Aging therapies
Casma Therapeutics	$154M	3	Autophagy
Aeovian Pharmaceuticals	$138M	4	mTOR drugs
Therini Bio	$101M	4	Neurodegeneration
Integrated Biosciences	$86M	2	AI drug discovery

This is a selection of therapeutic developers, not a separate ranking of all longevity medicines.

Is longevity funding finally getting drugs into human trials?

Yes, longevity medicines are reaching patients: Life Biosciences raised an $80M Series D+ in April 2026 to support its ER-100 clinical trial.

Life Biosciences dosed its first ER-100 patient in June 2026 after the FDA cleared a Phase 1 study in January 2026. The trial studies safety in people with glaucoma and another form of optic nerve damage. NewLimit's $435M Series C in June 2026 backs a plan to bring a reprogramming medicine into clinical studies. The projects differ, but both are moving from laboratory work toward tests in people.

There are also more focused age-related treatments. Tenpoint Therapeutics raised an $85M Series B in January 2026 as its YUVEZZI eye drops received FDA approval for age-related near-vision loss. Tenpoint also arranged a credit facility on the same day. Our total counts its equity financing, not that loan. Cognito Therapeutics raised a $105M Series C in March 2026 to prepare its light-and-sound Alzheimer's device for trial results and regulatory review.

Regulators authorize drugs for specific conditions, not for aging as a single disease. Tenpoint already has an approved product, while Life Biosciences is beginning safety testing and NewLimit is still preparing its first trial.

Are longevity testing startups raising more than clinics?

Not clearly: Human Longevity ($370M) and Function Health (at least $343M) lead the testing side, but Fountain Life, a clinic chain, has raised $188M, ahead of Prenuvo's $176M, and the scan-clinic business Neko Health has raised $1.0B.

Function Health announced a $298M Series B in November 2025 and described a service combining recurring lab tests with AI-assisted health interpretation. Neko Health takes a more clinic-centered route, making proprietary scans and clinician visits central to the product. Prenuvo reported its $120M Series B in February 2025, describing growth in whole-body MRI screening and new software-based assessment tools.

Lab-testing platforms can use existing laboratory networks, while scanner-led providers need imaging capacity and trained staff. Clinics also need local doctors and space. Everlab's June 2026 announcement illustrates another route: an AI-powered preventive-care platform that it plans to take abroad, starting with the United Kingdom.

Function Health now includes imaging as well as laboratory tests.

The table below shows selected preventive-health startups by lifetime funding, including both testing platforms and clinic-led businesses.

Startup	Raised	Rounds	Focus
Human Longevity	$370M	4	Genomic testing
Function Health	$343M+	2	Lab membership
Fountain Life	$188M	5	Preventive clinics
Prenuvo	$176M	2	MRI scanning
Viome	$157M	6	Microbiome testing
Q Bio	$85M	4	Health scans
Everlab	$58M	3	Preventive care
Lucis	$28M	2	Health platform

The selection includes different service models; the main ranking covers the full market.

Do longevity startups need round after round of funding?

Not always: 56 longevity startups have raised funding in a single equity round, while Insilico Medicine has recorded 11 rounds and Oura 10.

A count of rounds can hide quite different funding needs. Altos Labs started with a large launch commitment and did not need repeated conventional venture rounds. Insilico Medicine combined many private financings with an IPO, reflecting the long development cycle of a drug-discovery platform. Oura has repeatedly funded hardware development, international distribution, and a growing software service.

Insilico Medicine's December 2025 Hong Kong listing is a useful endpoint for that longer journey. The company described a business with its own drug pipeline and a platform for discovering medicines with AI.

A startup may stay at a single round because it sells to customers, has only just launched, or is not expanding. Insilico Medicine had to finance years of drug research before listing, while Oura kept funding manufacturing and international sales. The number of rounds alone cannot tell us whether either business is profitable.

Which longevity startups are still raising giant rounds?

Neko Health has the largest disclosed longevity round this year, a $700M Series C in July 2026, while WHOOP and NewLimit have also raised major rounds.

WHOOP's March 2026 financing supports international growth in connected health, and NewLimit's June 2026 financing is aimed at a future clinical medicine. Neko Health's funding is going toward preventive scanning sites and technology. The checks are large, yet they fund different activities with different routes to revenue and medical validation.

Smaller rounds also show where money is going. Cambrian Biopharma raised a $124M Growth Equity round in June 2026, Cognito Therapeutics a $105M Series C in March 2026, and Midi Health a $100M Series D+ in February 2026. Midi said it would expand care for women through menopause and beyond. Loyal's February 2026 Series C targets a regulatory path for a medicine intended to extend dogs' healthy lives.

This year's large rounds range from clinic openings to new drug trials.

The table below shows selected large 2026 financing rounds from our ranking, ordered by disclosed round size, rather than lifetime funding.

Startup	Round	Stage	Date
Neko Health	$700M	Series C	July 2026
WHOOP	$575M	Series D+	March 2026
NewLimit	$435M	Series C	June 2026
Cambrian Biopharma	$124M	Growth Equity	June 2026
Cognito Therapeutics	$105M	Series C	March 2026
Midi Health	$100M	Series D+	February 2026
Loyal	$100M	Series C	February 2026
Tenpoint Therapeutics	$85M	Series B	January 2026
Life Biosciences	$80M	Series D+	April 2026
Integrated Biosciences	$68M	undisclosed stage	July 2026
Eight Sleep	$50M	Series D+	March 2026

Stages are grouped consistently across the ranking; these are equity rounds, not credit facilities.

Can longevity drug startups go years without raising again?

Longevity drug startups can go years without new equity: Casma Therapeutics last reported a $46M Series C in November 2022, and Navitor Pharmaceuticals a $15M Series D+ in April 2020.

Casma Therapeutics has raised $154M in total and Navitor Pharmaceuticals $93M. Elevian has raised at least $59M, including a $40M Series A in September 2021. Each works on a difficult part of the biology of aging or related chronic disease, where clinical results and partnerships can matter more than the frequency of press releases about financing.

Other established companies have recently raised or reached a new stage. Insilico Medicine listed in Hong Kong in December 2025; Life Biosciences began human trials in 2026; and Tenpoint Therapeutics moved from development toward selling an approved presbyopia treatment. The capital needs of a listed drug developer, a clinical-stage biotech, and a new medical product differ.

Our ranking counts 26 companies whose last round was before 2023 and 58 whose last round was in 2026. Clinical study updates, partnerships, product launches, and regulatory decisions can move a drug developer forward even when the last financing date stays old.

Are US longevity startups the only ones raising huge amounts?

No, the United States has 97 longevity startups in our ranking, or 63%, but companies such as Finland's Oura and Sweden's Neko Health have also raised large sums.

The United Kingdom has 13 ranked startups, Switzerland 10, Sweden 3, and Finland 1. Oura is the only Finnish company in our ranking, while Sweden's Neko Health follows a different approach based on preventive clinics. A country can have fewer startups and still be home to a heavily funded business.

The European companies are also quite different. Oura has a global wearable and software business. Neko Health builds its own preventive scanning system and operates clinics. Switzerland's Timeline sells longevity supplements and skincare, while the United Kingdom's Tenpoint Therapeutics is commercializing a treatment for age-related near-vision loss. Each requires a different amount and type of capital.

There are challengers farther afield as well. Australian startup Everlab announced a major Series A in June 2026 to expand its preventive-care service, and China's Reju Therapeutics reported financing in October 2026 for aging-related drug work. The ranking covers 23 countries. Access to laboratories, clinicians, and customers affects where these companies expand, regardless of where they were founded.

Are investors backing longevity drugs for dogs and cats?

Yes, pet longevity medicines have real investor support: Loyal has raised $205M to develop a lifespan treatment for dogs.

Loyal announced a Series C in February 2026 to advance LOY-002, a drug program for extending the healthy lifespan of older dogs, toward FDA approval. The company is targeting a specific veterinary route rather than claiming that it can already slow aging in humans. A pet medicine can reach a more defined regulatory and customer setting, though it still needs convincing evidence and approval.

The field extends beyond Loyal. Animal Biosciences has raised at least $4.7M to work on companion-animal longevity therapies, while The Cat Health Company has raised $552K for lifespan-oriented drugs for cats. Loyal is pursuing an advanced regulatory program for dogs; the cat-focused and other animal-drug developers are earlier in development.

Owners already pay veterinarians for animal healthcare. Loyal said in February 2026 that the FDA had accepted major elements of its application for expanded conditional approval of LOY-002, and the company was preparing for a possible launch. Approval is not guaranteed, but the regulatory milestones help explain why Loyal has been able to attract investors.

Have IPOs changed which longevity startups raised the most?

Partly: Insilico Medicine has raised $874M in longevity funding, including a $337M IPO in December 2025, and BioAge Labs' $228M IPO sits inside its total.

Insilico Medicine listed on the Hong Kong Stock Exchange in December 2025 after years of private financing. Insilico Medicine has raised funds across 11 rounds and develops drugs through an AI discovery platform. BioAge Labs has raised at least $522M, including a $228M IPO in September 2024, as it develops medicines informed by aging biology. Going public changes how investors look at them, but both companies stay in our ranking.

BioAge Labs' public filings describe research work on metabolic diseases tied to human aging and report subsequent clinical and business developments. Insilico Medicine has reported drug-development activity and partnerships as a public company. Those milestones are easier to follow through official filings than the work of a smaller private startup.

An IPO headline can also mix newly issued shares with sales by existing owners. Oura's proposed 2026 offering, later postponed, would have included both types, according to its US securities filing. Selling a shareholder's existing shares does not give the company new operating capital. We count the money a company receives when it issues new IPO shares. We leave out secondary share sales and offerings that never close.

What does the longevity funding ranking tell us?

Altos Labs is the number one longevity startup by cumulative funding, with $3.0B committed at its January 2022 launch.

The market then divides into several ways of trying to extend healthy life. Oura and WHOOP have large wearable businesses; Neko Health and Function Health sell preventive information and services; NewLimit and Life Biosciences are working toward medicines. Investors are paying for very different products, customers, and scientific risks.

The gap in funding is still important. Only 3 longevity startups have reached at least $1B, while most companies operate with far smaller budgets. The largest research and consumer-health businesses can spend on laboratories, product distribution, and clinical teams at a scale the smaller startups cannot match.

Recent rounds continue to fund both services people can buy today and medicines still in development. Neko Health is opening clinics, NewLimit is preparing a clinical trial, and Loyal is working toward approval of a veterinary drug.

The funding ranking will change when companies raise new equity, complete IPOs with primary proceeds, or secure capital for more advanced clinical and commercial work. The bigger question is what that money delivers: treatments that work, preventive services with demonstrated benefit, and businesses that can keep customers without endless financing.